Trial Search Results

Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome

The purpose of this study is to determine whether the medication oxytocin is an effective and tolerable treatment in adolescent males with fragile X syndrome (FraX) for improving socially appropriate behaviors and reducing social anxiety.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Drug: placebo
  • Drug: oxytocin 24IU
  • Drug: oxytocin 48IU


Phase 2


Inclusion Criteria:

   1. Confirmed genetic diagnosis of Fragile X (FraX) (full mutation).

   2. Male (who have more serious effects due to the X chromosome nature of the disorder)

   3. Age 13-29 years.

   4. Parent of adolescent must be willing to sign informed consent.

   5. Intelligence Quotient (IQ) > 42.

Exclusion Criteria:

   1. Cardiac risk factors.

   2. Medication exclusions: opiates or opiate antagonists, corticosteroids, typical or
   atypical antipsychotics.

Ages Eligible for Study

13 Years - 29 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Scott Hall